Biotech by P/B ratio
Share price divided by book value per share: what the market pays for each dollar of shareholders' equity on the balance sheet.
Biogen has the lowest figure of the 18 biotech ranked by P/B ratio, at 2.0, followed by Vaxcyte (3.5) and Neurocrine Biosciences (4.3). Figures as of 18 Nov 2026, 15:16 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 18
- Lowest
- Biogen2.0
- Median
- 9.1
- Combined market value
- SAR 3.18T
- Countries
- 5
- Not ranked
- 6no P/B ratio on file
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | P/B ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | BiogenBIIB · Health Care | 2.0 | SAR 138.6B | SAR 937.86 | 0.30% down | 49% up | ||
| 2 | VaxcytePCVX · Health Care | 3.5 | SAR 35.1B | SAR 221.42 | 0.62% down | 22% up | ||
| 3 | Neurocrine BiosciencesNBIX · Health Care | 4.3 | SAR 61.9B | SAR 611.34 | 1.77% down | 20% up | ||
| 4 | RepligenRGEN · Health Care | 4.7 | SAR 41.3B | SAR 646.45 | 6.26% up | 5% up | ||
| 5 | Bio-TechneTECH · Health Care | 5.3 | SAR 42.8B | SAR 272.70 | 0.10% up | 26% up | ||
| 6 | Krystal BiotechKRYS · Health Care | 6.4 | SAR 34.4B | SAR 1,161.68 | 3.73% up | 46% up | ||
| 7 | Kymera TherapeuticsKYMR · Health Care | 6.5 | SAR 39.3B | SAR 459.80 | 0.87% up | 87% up | ||
| 8 | CG OncologyCGON · Health Care | 7.1 | SAR 26.6B | SAR 297.53 | 0.48% up | 85% up | ||
| 9 | Twist BioscienceTWST · Health Care | 9.0 | SAR 30.2B | SAR 443.56 | 5.58% up | 340% up | ||
| 10 | ExelixisEXEL · Health Care | 9.2 | SAR 63.4B | SAR 259.78 | 1.10% up | 63% up | ||
| 11 | ImmunovantIMVT · Health Care | 10.6 | SAR 26.2B | SAR 126.67 | 1.69% up | 43% up | ||
| 12 | ModernaMRNA · Health Care | 12.2 | SAR 313.2B | SAR 774.09 | 0.21% down | 755% up | ||
| 13 | Revolution MedicinesRVMD · Health Care | 14.6 | SAR 131.5B | SAR 608.15 | 0.34% down | 131% up | ||
| 14 | Gilead SciencesGILD · Health Care | 16.1 | SAR 787.1B | SAR 634.59 | 0.63% down | 33% up | ||
| 15 | AmgenAMGN · Health Care | 17.0 | SAR 913.9B | SAR 1,689.49 | 1.64% down | 34% up | ||
| 16 | Adaptive BiotechnologiesADPT · Health Care | 26.5 | SAR 17.5B | SAR 108.39 | 1.43% up | 88% up | ||
| 17 | Scholar Rock HoldingSRRK · Health Care | 34.4 | SAR 21.8B | SAR 178.66 | 5.66% up | 14% up | ||
| 18 | Kodiak SciencesKOD · Health Care | 504 | SAR 24.2B | SAR 370.79 | 2.12% up | 396% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 3.7510 SAR). 6 companies have no P/B ratio on file and are not ranked here.
Questions and answers
Which biotech have the lowest P/B ratio?
Biogen (2.0), Vaxcyte (3.5) and Neurocrine Biosciences (4.3) have the lowest P/B ratio of the 18 biotech ranked here as of 18 Nov 2026, 15:16 UTC.
How many biotech are in this ranking?
18 are ranked by P/B ratio. 6 more have no P/B ratio on file and are left out rather than ranked at zero.
What are these biotech worth together?
The 18 biotech ranked by P/B ratio have a combined market value of SAR 3.18T as of 18 Nov 2026, 15:16 UTC.
What does ranking by P/B ratio measure?
Share price divided by book value per share: what the market pays for each dollar of shareholders' equity on the balance sheet.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Piotroski F-score: the nine tests and what they show
The Piotroski F-score is a 0–9 count of simple accounting tests a company passes: four on profitability, three on debt, liquidity and share issuance, two on operating efficiency. Joseph Piotroski's 2000 paper found that among cheap, high book-to-market stocks, high scorers went on to beat low scorers. It is a screen of financial health, not a valuation.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Biotech by P/B ratio”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=pb-ratio
Underlying data: Yahoo Finance; SEC EDGAR.